Head And Neck Cancer – Pipeline Review, H1 2018

Global Markets Direct’s, ‘Head And Neck Cancer – Pipeline Review, H1 2018’, provides an overview of the Head And Neck Cancer pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Head And Neck Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Head And Neck Cancer and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Head And Neck Cancer

– The report reviews pipeline therapeutics for Head And Neck Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Head And Neck Cancer therapeutics and enlists all their major and minor projects

– The report assesses Head And Neck Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Head And Neck Cancer

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Head And Neck Cancer

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Head And Neck Cancer pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

3SBio Inc

4SC AG

AbbVie Inc

Abion Inc

Adaptimmune Therapeutics Plc

Admedus Ltd

Aduro BioTech Inc

Advaxis Inc

Advenchen Laboratories LLC

Affimed GmbH

Altor BioScience Corp

Ambrx Inc

amcure GmbH

Amgen Inc

arGEN-X BV

ArQule Inc

Array BioPharma Inc

Ascentage Pharma Group Corp Ltd

Aspyrian Therapeutics Inc

Astellas Pharma Inc

Astex Pharmaceuticals Inc

AstraZeneca Plc

Atara Biotherapeutics Inc

Aurigene Discovery Technologies Ltd

AVEO Pharmaceuticals Inc

Bayer AG

BeiGene Ltd

Benitec Biopharma Ltd

Bexion Pharmaceuticals LLC

Bicycle Therapeutics Ltd

BioDiem Ltd

Biohaven Pharmaceutical Holding Company Ltd

Biomics Biotechnologies Co Ltd

Bionovis SA

BioNTech AG

Biothera Pharmaceutical Inc

Boehringer Ingelheim GmbH

Boston Biomedical Inc

Bristol-Myers Squibb Co

CBT Pharmaceuticals Inc

CEL-SCI Corp

Celgene Corp

Cell Medica Ltd

Celldex Therapeutics Inc

Cellectar Biosciences Inc

Celprogen Inc

Checkpoint Therapeutics Inc

Corvus Pharmaceuticals Inc

Cotinga Pharmaceuticals Inc

Cristal Therapeutics BV

Curevac AG

Cyclacel Pharmaceuticals Inc

CytImmune Sciences Inc

CytomX Therapeutics Inc

Daiichi Sankyo Co Ltd

Denceptor Therapeutics Ltd

DNJ Pharma Inc

Dynavax Technologies Corp

Eisai Co Ltd

Eli Lilly and Co

Enzene Biosciences Ltd

Etubics Corp

Eureka Therapeutics Inc

Exelixis Inc

F. Hoffmann-La Roche Ltd

Fate Therapeutics Inc

Formation Biologics Inc

Forty Seven Inc

Fujifilm Holdings Corporation

G&E Herbal Biotechnology Co Ltd

Galectin Therapeutics Inc

Genelux Corp

Genentech Inc

GeneSegues Inc

Genmab A/S

GlaxoSmithKline Plc

Glenmark Pharmaceuticals Ltd

Gliknik Inc

Glycotope GmbH

Hanmi Pharmaceuticals Co Ltd

Harbin Gloria Pharmaceuticals Co Ltd

Hookipa Biotech AG

Horizon Pharma Plc

Hutchison MediPharma Ltd

Idera Pharmaceuticals Inc

Ignyta Inc

Immatics Biotechnologies GmbH

Immunocore Ltd

Immunomedics Inc

Immunovaccine Inc

Immunovative Therapies Ltd

Immutep Ltd

Incyte Corp

Infinity Pharmaceuticals Inc

Innate Pharma SA

Inovio Pharmaceuticals Inc

InteRNA Technologies BV

Iovance Biotherapeutics Inc

IRX Therapeutics Inc

ISA Pharmaceuticals BV

ISU ABXIS Co Ltd

Jiangsu Hengrui Medicine Co Ltd

Jiangsu Kanion Pharmaceutical Co Ltd

Johnson & Johnson

Jounce Therapeutics Inc

Juno Therapeutics Inc

Kite Pharma Inc

Kura Oncology Inc

Laboratoires Pierre Fabre SA

LATITUDE Pharmaceuticals Inc

Loxo Oncology Inc

Lycera Corp

Lytix Biopharma AS

Mabion SA

MacroGenics Inc

Madrigal Pharmaceuticals Inc.

Marsala Biotech Inc

Mateon Therapeutics Inc

MaxiVAX SA

MedImmune LLC

Merck & Co Inc

Merck KGaA

Merrimack Pharmaceuticals Inc

Mersana Therapeutics Inc

Millennium Pharmaceuticals Inc

Mirati Therapeutics Inc

Moderna Therapeutics Inc

Molecular Partners AG

Molecular Templates Inc

Moleculin Biotech Inc

NanoCarrier Co Ltd

NantKwest Inc

Natco Pharma Ltd

NeoImmuneTech Inc

Neonc Technologies Inc

Neumedicines Inc

Novartis AG

Noxopharm Ltd

Oncobiologics Inc

Oncolys BioPharma Inc

Onconova Therapeutics Inc

Oncovir Inc

Ono Pharmaceutical Co Ltd

Otsuka Holdings Co Ltd

Oxford Vacmedix UK Ltd

PDS Biotechnology Corp

Pfizer Inc

Pharma Mar SA

Phosplatin Therapeutics LLC

Plexxikon Inc

PNP Therapeutics Inc

Profectus BioSciences Inc

Provectus Biopharmaceuticals Inc

PsiOxus Therapeutics Ltd

R Pharm

Regeneron Pharmaceuticals Inc

Reliance Life Sciences Pvt Ltd

Sareum Holdings Plc

Selecta Biosciences Inc

Shanghai Henlius Biotech Co Ltd

Shionogi & Co Ltd

Sierra Oncology Inc

Sillajen Biotherapeutics

Sinil Pharmaceutical Co Ltd

Soricimed Biopharma Inc

Sorrento Therapeutics Inc

Sound Pharmaceuticals Inc

Spherium Biomed SL

Sumitomo Dainippon Pharma Co Ltd

SuviCa Inc

SynCore Biotechnology Co Ltd

Systimmune Inc

Takis Srl

Tessa Therapeutics Pte Ltd

Theralase Technologies Inc

Theravectys SA

Tolero Pharmaceuticals Inc

Tosk Inc

Transgene SA

UbiVac LLC

Vaccibody AS

VasGene Therapeutics Inc

Vault Pharma Inc

Vaxeal Holding SA

Vectorite Biomedical Inc

Viracta Therapeutics Inc

Vyriad Inc

Table of Contents

Table of Contents

Table of Contents 2

Introduction 10

Head And Neck Cancer Overview 11

Head And Neck Cancer Therapeutics Development 12

Head And Neck Cancer Therapeutics Assessment 59

Head And Neck Cancer Companies Involved in Therapeutics Development 88

Head And Neck Cancer Drug Profiles 177

Head And Neck Cancer Dormant Projects 1569

Head And Neck Cancer Discontinued Products 1582

Head And Neck Cancer Product Development Milestones 1585

Appendix 1601

List of Tables

List of Tables

Table 1: Number of Products under Development for Head And Neck Cancer, H1 2018 49

Table 2: Number of Products under Development by Companies, H1 2018 51

Table 3: Number of Products under Development by Companies, H1 2018 (Contd..1), H1 2018 52

Table 4: Number of Products under Development by Companies, H1 2018 (Contd..2), H1 2018 53

Table 5: Number of Products under Development by Companies, H1 2018 (Contd..3), H1 2018 54

Table 6: Number of Products under Development by Companies, H1 2018 (Contd..4), H1 2018 55

Table 7: Number of Products under Development by Companies, H1 2018 (Contd..5), H1 2018 56

Table 8: Number of Products under Development by Companies, H1 2018 (Contd..6), H1 2018 57

Table 9: Number of Products under Development by Companies, H1 2018 (Contd..7), H1 2018 58

Table 10: Number of Products under Development by Companies, H1 2018 (Contd..8), H1 2018 59

Table 11: Number of Products under Development by Companies, H1 2018 (Contd..9), H1 2018 60

Table 12: Number of Products under Development by Companies, H1 2018 (Contd..10), H1 2018 61

Table 13: Number of Products under Development by Companies, H1 2018 (Contd..11), H1 2018 62

Table 14: Number of Products under Development by Companies, H1 2018 (Contd..12), H1 2018 63

Table 15: Number of Products under Development by Universities/Institutes, H1 2018 64

Table 16: Number of Products under Development by Universities/Institutes, H1 2018 (Contd..1), H1 2018 66

Table 17: Products under Development by Companies, H1 2018 67

Table 18: Products under Development by Companies, H1 2018 (Contd..1), H1 2018 68

Table 19: Products under Development by Companies, H1 2018 (Contd..2), H1 2018 69

Table 20: Products under Development by Companies, H1 2018 (Contd..3), H1 2018 70

Table 21: Products under Development by Companies, H1 2018 (Contd..4), H1 2018 71

Table 22: Products under Development by Companies, H1 2018 (Contd..5), H1 2018 72

Table 23: Products under Development by Companies, H1 2018 (Contd..6), H1 2018 73

Table 24: Products under Development by Companies, H1 2018 (Contd..7), H1 2018 74

Table 25: Products under Development by Companies, H1 2018 (Contd..8), H1 2018 75

Table 26: Products under Development by Companies, H1 2018 (Contd..9), H1 2018 76

Table 27: Products under Development by Companies, H1 2018 (Contd..10), H1 2018 77

Table 28: Products under Development by Companies, H1 2018 (Contd..11), H1 2018 78

Table 29: Products under Development by Companies, H1 2018 (Contd..12), H1 2018 79

Table 30: Products under Development by Companies, H1 2018 (Contd..13), H1 2018 80

Table 31: Products under Development by Companies, H1 2018 (Contd..14), H1 2018 81

Table 32: Products under Development by Companies, H1 2018 (Contd..15), H1 2018 82

Table 33: Products under Development by Companies, H1 2018 (Contd..16), H1 2018 83

Table 34: Products under Development by Companies, H1 2018 (Contd..17), H1 2018 84

Table 35: Products under Development by Companies, H1 2018 (Contd..18), H1 2018 85

Table 36: Products under Development by Companies, H1 2018 (Contd..19), H1 2018 86

Table 37: Products under Development by Companies, H1 2018 (Contd..20), H1 2018 87

Table 38: Products under Development by Companies, H1 2018 (Contd..21), H1 2018 88

Table 39: Products under Development by Companies, H1 2018 (Contd..22), H1 2018 89

Table 40: Products under Development by Companies, H1 2018 (Contd..23), H1 2018 90

Table 41: Products under Development by Companies, H1 2018 (Contd..24), H1 2018 91

Table 42: Products under Development by Universities/Institutes, H1 2018 92

Table 43: Products under Development by Universities/Institutes, H1 2018 (Contd..1), H1 2018 94

Table 44: Products under Development by Universities/Institutes, H1 2018 (Contd..2), H1 2018 95

Table 45: Number of Products by Stage and Target, H1 2018 98

Table 46: Number of Products by Stage and Target, H1 2018 (Contd..1), H1 2018 99

Table 47: Number of Products by Stage and Target, H1 2018 (Contd..2), H1 2018 100

Table 48: Number of Products by Stage and Target, H1 2018 (Contd..3), H1 2018 101

Table 49: Number of Products by Stage and Target, H1 2018 (Contd..4), H1 2018 102

Table 50: Number of Products by Stage and Target, H1 2018 (Contd..5), H1 2018 103

Table 51: Number of Products by Stage and Target, H1 2018 (Contd..6), H1 2018 104

Table 52: Number of Products by Stage and Target, H1 2018 (Contd..7), H1 2018 105

Table 53: Number of Products by Stage and Target, H1 2018 (Contd..8), H1 2018 106

Table 54: Number of Products by Stage and Mechanism of Action, H1 2018 109

Table 55: Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..1), H1 2018 110

Table 56: Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..2), H1 2018 111

Table 57: Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..3), H1 2018 112

Table 58: Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..4), H1 2018 113

Table 59: Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..5), H1 2018 114

Table 60: Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..6), H1 2018 115

Table 61: Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..7), H1 2018 116

Table 62: Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..8), H1 2018 117

Table 63: Number of Products by Stage and Route of Administration, H1 2018 120

Table 64: Number of Products by Stage and Molecule Type, H1 2018 123

Table 65: Number of Products by Stage and Molecule Type, H1 2018 (Contd..1), H1 2018 124

Table 66: Head And Neck Cancer Pipeline by 3SBio Inc, H1 2018 125

Table 67: Head And Neck Cancer Pipeline by 4SC AG, H1 2018 125

Table 68: Head And Neck Cancer Pipeline by AbbVie Inc, H1 2018 126

Table 69: Head And Neck Cancer Pipeline by Abion Inc, H1 2018 126

Table 70: Head And Neck Cancer Pipeline by Adaptimmune Therapeutics Plc, H1 2018 127

List of Figures

List of Figures

Figure 1: Number of Products under Development for Head And Neck Cancer, H1 2018 49

Figure 2: Number of Products under Development by Companies, H1 2018 50

Figure 3: Number of Products under Development by Universities/Institutes, H1 2018 64

Figure 4: Number of Products by Top 10 Targets, H1 2018 96

Figure 5: Number of Products by Stage and Top 10 Targets, H1 2018 97

Figure 6: Number of Products by Top 10 Mechanism of Actions, H1 2018 107

Figure 7: Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018 108

Figure 8: Number of Products by Top 10 Routes of Administration, H1 2018 118

Figure 9: Number of Products by Stage and Top 10 Routes of Administration, H1 2018 119

Figure 10: Number of Products by Top 10 Molecule Types, H1 2018 121

Figure 11: Number of Products by Stage and Top 10 Molecule Types, H1 2018 122

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2960

Saved reports